1.Protective effects of Shuangyi Qushi Tongluo Capsules on dexamethasone-induced osteoporosis in mice
Yi LI ; Jian-bin HE ; Jia-xiu XIE ; Quan-mou LUO ; Dong-mei LI ; Jun-hui HE ; Dong-mei WEI ; Chao WEI ; Hong-cong QIU ; Gui-ning WEI ; Bo WANG
Chinese Traditional Patent Medicine 2025;47(6):1834-1842
AIM To investigate the protective effects of Shuangyi Qushi Tongluo Capsules(Shuangyi Capsules)on Dexamethasone(Dex)induced osteoporosis in mice.METHODS The C57BL/6J mice were randomly divided into the control group,the model group,the Xianling Gubao Capsules group(1.5 g/kg),and the low-dose,moderate-dose,and high-dose Shuangyi Capsules groups(0.6,1.2,and 2.4 g/kg).The mouse model of osteoporosis was induced by 8-week intraperitoneal injection of Dex sodium phosphate injection(5 mg/kg).The mice had their femur osteogenesis observed with hematoxylin and eosin(HE)staining and tartrate-resistant acid phosphatase(TRAP)staining;their serum alkaline phosphatase(ALP)and osteocalcin(BGP)activities detected by ELISA;their femoral mRNA expressions of Col-Ⅰ,OCN,and OPN detected by RT-qPCR;and their femoral protein expressions of OPG and RANKL detected by Western blot.Upon the MC3T3-E1 cells exposed to Dex and Shuangyi Capsules,their viability was evaluated by CCK-8 assay;their mineralization determined by alkaline phosphatase staining and alizarin red staining(ARS);and their intracellular ROS level detected using DCFH-DA probe.RESULTS Compared with the model group,Shuangyi Capsules groups demonstrated improved fracture of femoral trabeculae and reduced number of osteoclasts;increased serum ALP and BGP activities(P<0.05,P<0.01);increased femoral expressions of Col-Ⅰ mRNA and OPG protein(P<0.05,P<0.01);and decreased RANKL protein expression(P<0.05).Compared with the MC3T3-E1 cells stimulated by Dex,those underwent further treatment of Shuangyi Capsules demonstrated increased cell viability and ALP activity(P<0.05,P<0.01);increased mineralization and calcium nodule formation;increased expressions of Col-Ⅰ,OCN,OPN mRNA and OPG protein(P<0.05,P<0.01);decreased RANKL protein expression(P<0.05,P<0.01);and reduced ROS levels.CONCLUSION Shuangyi Capsules ameliorate Dex-induced osteoporosis in mice by suppressing osteoclast overactivation,enhancing osteoblast activity,and stimulating bone formation through modulation of Col-Ⅰ,OCN,OPN mRNA and OPG/RANKL protein levels.
2.Protective effects of Shuangyi Qushi Tongluo Capsules on dexamethasone-induced osteoporosis in mice
Yi LI ; Jian-bin HE ; Jia-xiu XIE ; Quan-mou LUO ; Dong-mei LI ; Jun-hui HE ; Dong-mei WEI ; Chao WEI ; Hong-cong QIU ; Gui-ning WEI ; Bo WANG
Chinese Traditional Patent Medicine 2025;47(6):1834-1842
AIM To investigate the protective effects of Shuangyi Qushi Tongluo Capsules(Shuangyi Capsules)on Dexamethasone(Dex)induced osteoporosis in mice.METHODS The C57BL/6J mice were randomly divided into the control group,the model group,the Xianling Gubao Capsules group(1.5 g/kg),and the low-dose,moderate-dose,and high-dose Shuangyi Capsules groups(0.6,1.2,and 2.4 g/kg).The mouse model of osteoporosis was induced by 8-week intraperitoneal injection of Dex sodium phosphate injection(5 mg/kg).The mice had their femur osteogenesis observed with hematoxylin and eosin(HE)staining and tartrate-resistant acid phosphatase(TRAP)staining;their serum alkaline phosphatase(ALP)and osteocalcin(BGP)activities detected by ELISA;their femoral mRNA expressions of Col-Ⅰ,OCN,and OPN detected by RT-qPCR;and their femoral protein expressions of OPG and RANKL detected by Western blot.Upon the MC3T3-E1 cells exposed to Dex and Shuangyi Capsules,their viability was evaluated by CCK-8 assay;their mineralization determined by alkaline phosphatase staining and alizarin red staining(ARS);and their intracellular ROS level detected using DCFH-DA probe.RESULTS Compared with the model group,Shuangyi Capsules groups demonstrated improved fracture of femoral trabeculae and reduced number of osteoclasts;increased serum ALP and BGP activities(P<0.05,P<0.01);increased femoral expressions of Col-Ⅰ mRNA and OPG protein(P<0.05,P<0.01);and decreased RANKL protein expression(P<0.05).Compared with the MC3T3-E1 cells stimulated by Dex,those underwent further treatment of Shuangyi Capsules demonstrated increased cell viability and ALP activity(P<0.05,P<0.01);increased mineralization and calcium nodule formation;increased expressions of Col-Ⅰ,OCN,OPN mRNA and OPG protein(P<0.05,P<0.01);decreased RANKL protein expression(P<0.05,P<0.01);and reduced ROS levels.CONCLUSION Shuangyi Capsules ameliorate Dex-induced osteoporosis in mice by suppressing osteoclast overactivation,enhancing osteoblast activity,and stimulating bone formation through modulation of Col-Ⅰ,OCN,OPN mRNA and OPG/RANKL protein levels.
3.Kaempferol-A Natural Drug for Rheumatoid Arthritis.
Hong-Mei HONG ; Jia-Wang ZHOU ; Ming-Yu LI ; Gui-Feng HAO ; Zhi-Jun XIE
Chinese journal of integrative medicine 2025;31(12):1119-1128
4.International clinical practice guideline on the use of traditional Chinese medicine for functional dyspepsia (2025).
Sheng-Sheng ZHANG ; Lu-Qing ZHAO ; Xiao-Hua HOU ; Zhao-Xiang BIAN ; Jian-Hua ZHENG ; Hai-He TIAN ; Guan-Hu YANG ; Won-Sook HONG ; Yu-Ying HE ; Li LIU ; Hong SHEN ; Yan-Ping LI ; Sheng XIE ; Jin SHU ; Bin-Fang ZENG ; Jun-Xiang LI ; Zhen LIU ; Zheng-Hua XIAO ; Jing-Dong XIAO ; Pei-Yong ZHENG ; Shao-Gang HUANG ; Sheng-Liang CHEN ; Gui-Jun FEI
Journal of Integrative Medicine 2025;23(5):502-518
Functional dyspepsia (FD), characterized by persistent or recurrent dyspeptic symptoms without identifiable organic, systemic or metabolic causes, is an increasingly recognized global health issue. The objective of this guideline is to equip clinicians and nursing professionals with evidence-based strategies for the management and treatment of adult patients with FD using traditional Chinese medicine (TCM). The Guideline Development Group consulted existing TCM consensus documents on FD and convened a panel of 35 clinicians to generate initial clinical queries. To address these queries, a systematic literature search was conducted across PubMed, EMBASE, the Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP Database, China Biology Medicine (SinoMed) Database, Wanfang Database, Traditional Medicine Research Data Expanded (TMRDE), and the Traditional Chinese Medical Literature Analysis and Retrieval System (TCMLARS). The evidence from the literature was critically appraised using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. The strength of the recommendations was ascertained through a consensus-building process involving TCM and allopathic medicine experts, methodologists, pharmacologists, nursing specialists, and health economists, leveraging their collective expertise and empirical knowledge. The guideline comprises a total of 43 evidence-informed recommendations that span a range of clinical aspects, including the pathogenesis according to TCM, diagnostic approaches, therapeutic interventions, efficacy assessments, and prognostic considerations. Please cite this article as: Zhang SS, Zhao LQ, Hou XH, Bian ZX, Zheng JH, Tian HH, Yang GH, Hong WS, He YY, Liu L, Shen H, Li YP, Xie S, Shu J, Zeng BF, Li JX, Liu Z, Xiao ZH, Xiao JD, Zheng PY, Huang SG, Chen SL, Fei GJ. International clinical practice guideline on the use of traditional Chinese medicine for functional dyspepsia (2025). J Integr Med. 2025; 23(5):502-518.
Dyspepsia/drug therapy*
;
Humans
;
Medicine, Chinese Traditional/methods*
;
Practice Guidelines as Topic
;
Drugs, Chinese Herbal/therapeutic use*
5.Diagnostic value of monocyte chemotactic protein-1 and creatine kinase isoenzyme for chronic heart failure
Qi-gui YU ; Jun XIE ; Lin-lin YANG
Chinese Journal of cardiovascular Rehabilitation Medicine 2025;34(4):470-474
Objective:To explore the diagnostic efficacy of monocyte chemotactic protein-1(MCP-1)and creatine kinase isoenzyme(CK-MB)for chronic heart failure(CHF)and their association with New York Heart Associa-tion(NYHA)class.Methods:A total of 300 patients suspected of CHF who underwent physical examination in the Second People's Hospital of Hefei between January 2020 and August 2021 were analyzed.After 3-month follow-up,a total of 150 patients were diagnosed with CHF.According to NYHA cardiac function classification,CHF pa-tients were divided into class Ⅱ group(n=45),class Ⅲ group(n=45)and class Ⅳ group(n=60).MCP-1 and CK-MB levels were compared among above groups.Receiver operating characteristic(ROC)curve was used to an-alyze the diagnostic efficacy of each index and their combination for CHF and their association with NYHA class were analyzed using Spearman correlation analysis.Results:Compared to those without CHF,patients with CHF had significant higher levels of MCP-1[96.01(86.21,124.28)ng/ml vs.25.38(22.79,28.72)ng/ml,P<0.001]and CK-MB[46.26(32.74,59.72)U/L vs.19.09(18.61,19.87)U/L,P<0.001].ROC curve showed that a combination of MCP-1 and CK-MB had a significant higher area under the ROC curve(AUC)(0.947,95%CI 0.915~0.969)than MCP-1(0.797,95%CI 0.747~0.841)or CK-MB(0.855,95%CI 0.810~0.893)alone(Z=4.543,3.170,P<0.001 all).Compared to those in the class Ⅱ group,those in the class Ⅲgroup and class Ⅳ group had significant higher MCP-1[94.57(91.18,96.92)ng/ml vs.125.27(123.20,128.24)ng/ml vs.68.38(27.55,86.38)ng/ml]and CK-MB[48.04(45.66,51.47)U/L vs.61.01(58.81,62.96)U/L vs.31.75(25.08,33.57)U/L],and those of class Ⅳ group were significantly higher than those of class Ⅲ group(P<0.001 all).Spearman correlation analysis indicated that the levels of MCP-1 and CK-MB were significant positively correlated with NYHA class in CHF patients(r=0.712,0.878,P<0.001 both).Con-clusion:MCP-1 and CK-MB were abnormally elevated in CHF patients.Serum levels of MCP-1 and CK-MB are significantly correlated with NYHA class.The combination had high diagnostic efficacy for CHF.
6.Diagnostic value of monocyte chemotactic protein-1 and creatine kinase isoenzyme for chronic heart failure
Qi-gui YU ; Jun XIE ; Lin-lin YANG
Chinese Journal of cardiovascular Rehabilitation Medicine 2025;34(4):470-474
Objective:To explore the diagnostic efficacy of monocyte chemotactic protein-1(MCP-1)and creatine kinase isoenzyme(CK-MB)for chronic heart failure(CHF)and their association with New York Heart Associa-tion(NYHA)class.Methods:A total of 300 patients suspected of CHF who underwent physical examination in the Second People's Hospital of Hefei between January 2020 and August 2021 were analyzed.After 3-month follow-up,a total of 150 patients were diagnosed with CHF.According to NYHA cardiac function classification,CHF pa-tients were divided into class Ⅱ group(n=45),class Ⅲ group(n=45)and class Ⅳ group(n=60).MCP-1 and CK-MB levels were compared among above groups.Receiver operating characteristic(ROC)curve was used to an-alyze the diagnostic efficacy of each index and their combination for CHF and their association with NYHA class were analyzed using Spearman correlation analysis.Results:Compared to those without CHF,patients with CHF had significant higher levels of MCP-1[96.01(86.21,124.28)ng/ml vs.25.38(22.79,28.72)ng/ml,P<0.001]and CK-MB[46.26(32.74,59.72)U/L vs.19.09(18.61,19.87)U/L,P<0.001].ROC curve showed that a combination of MCP-1 and CK-MB had a significant higher area under the ROC curve(AUC)(0.947,95%CI 0.915~0.969)than MCP-1(0.797,95%CI 0.747~0.841)or CK-MB(0.855,95%CI 0.810~0.893)alone(Z=4.543,3.170,P<0.001 all).Compared to those in the class Ⅱ group,those in the class Ⅲgroup and class Ⅳ group had significant higher MCP-1[94.57(91.18,96.92)ng/ml vs.125.27(123.20,128.24)ng/ml vs.68.38(27.55,86.38)ng/ml]and CK-MB[48.04(45.66,51.47)U/L vs.61.01(58.81,62.96)U/L vs.31.75(25.08,33.57)U/L],and those of class Ⅳ group were significantly higher than those of class Ⅲ group(P<0.001 all).Spearman correlation analysis indicated that the levels of MCP-1 and CK-MB were significant positively correlated with NYHA class in CHF patients(r=0.712,0.878,P<0.001 both).Con-clusion:MCP-1 and CK-MB were abnormally elevated in CHF patients.Serum levels of MCP-1 and CK-MB are significantly correlated with NYHA class.The combination had high diagnostic efficacy for CHF.
7.Chinese expert consensus on blood support mode and blood transfusion strategies for emergency treatment of severe trauma patients (version 2024)
Yao LU ; Yang LI ; Leiying ZHANG ; Hao TANG ; Huidan JING ; Yaoli WANG ; Xiangzhi JIA ; Li BA ; Maohong BIAN ; Dan CAI ; Hui CAI ; Xiaohong CAI ; Zhanshan ZHA ; Bingyu CHEN ; Daqing CHEN ; Feng CHEN ; Guoan CHEN ; Haiming CHEN ; Jing CHEN ; Min CHEN ; Qing CHEN ; Shu CHEN ; Xi CHEN ; Jinfeng CHENG ; Xiaoling CHU ; Hongwang CUI ; Xin CUI ; Zhen DA ; Ying DAI ; Surong DENG ; Weiqun DONG ; Weimin FAN ; Ke FENG ; Danhui FU ; Yongshui FU ; Qi FU ; Xuemei FU ; Jia GAN ; Xinyu GAN ; Wei GAO ; Huaizheng GONG ; Rong GUI ; Geng GUO ; Ning HAN ; Yiwen HAO ; Wubing HE ; Qiang HONG ; Ruiqin HOU ; Wei HOU ; Jie HU ; Peiyang HU ; Xi HU ; Xiaoyu HU ; Guangbin HUANG ; Jie HUANG ; Xiangyan HUANG ; Yuanshuai HUANG ; Shouyong HUN ; Xuebing JIANG ; Ping JIN ; Dong LAI ; Aiping LE ; Hongmei LI ; Bijuan LI ; Cuiying LI ; Daihong LI ; Haihong LI ; He LI ; Hui LI ; Jianping LI ; Ning LI ; Xiying LI ; Xiangmin LI ; Xiaofei LI ; Xiaojuan LI ; Zhiqiang LI ; Zhongjun LI ; Zunyan LI ; Huaqin LIANG ; Xiaohua LIANG ; Dongfa LIAO ; Qun LIAO ; Yan LIAO ; Jiajin LIN ; Chunxia LIU ; Fenghua LIU ; Peixian LIU ; Tiemei LIU ; Xiaoxin LIU ; Zhiwei LIU ; Zhongdi LIU ; Hua LU ; Jianfeng LUAN ; Jianjun LUO ; Qun LUO ; Dingfeng LYU ; Qi LYU ; Xianping LYU ; Aijun MA ; Liqiang MA ; Shuxuan MA ; Xainjun MA ; Xiaogang MA ; Xiaoli MA ; Guoqing MAO ; Shijie MU ; Shaolin NIE ; Shujuan OUYANG ; Xilin OUYANG ; Chunqiu PAN ; Jian PAN ; Xiaohua PAN ; Lei PENG ; Tao PENG ; Baohua QIAN ; Shu QIAO ; Li QIN ; Ying REN ; Zhaoqi REN ; Ruiming RONG ; Changshan SU ; Mingwei SUN ; Wenwu SUN ; Zhenwei SUN ; Haiping TANG ; Xiaofeng TANG ; Changjiu TANG ; Cuihua TAO ; Zhibin TIAN ; Juan WANG ; Baoyan WANG ; Chunyan WANG ; Gefei WANG ; Haiyan WANG ; Hongjie WANG ; Peng WANG ; Pengli WANG ; Qiushi WANG ; Xiaoning WANG ; Xinhua WANG ; Xuefeng WANG ; Yong WANG ; Yongjun WANG ; Yuanjie WANG ; Zhihua WANG ; Shaojun WEI ; Yaming WEI ; Jianbo WEN ; Jun WEN ; Jiang WU ; Jufeng WU ; Aijun XIA ; Fei XIA ; Rong XIA ; Jue XIE ; Yanchao XING ; Yan XIONG ; Feng XU ; Yongzhu XU ; Yongan XU ; Yonghe YAN ; Beizhan YAN ; Jiang YANG ; Jiangcun YANG ; Jun YANG ; Xinwen YANG ; Yongyi YANG ; Chunyan YAO ; Mingliang YE ; Changlin YIN ; Ming YIN ; Wen YIN ; Lianling YU ; Shuhong YU ; Zebo YU ; Yigang YU ; Anyong YU ; Hong YUAN ; Yi YUAN ; Chan ZHANG ; Jinjun ZHANG ; Jun ZHANG ; Kai ZHANG ; Leibing ZHANG ; Quan ZHANG ; Rongjiang ZHANG ; Sanming ZHANG ; Shengji ZHANG ; Shuo ZHANG ; Wei ZHANG ; Weidong ZHANG ; Xi ZHANG ; Xingwen ZHANG ; Guixi ZHANG ; Xiaojun ZHANG ; Guoqing ZHAO ; Jianpeng ZHAO ; Shuming ZHAO ; Beibei ZHENG ; Shangen ZHENG ; Huayou ZHOU ; Jicheng ZHOU ; Lihong ZHOU ; Mou ZHOU ; Xiaoyu ZHOU ; Xuelian ZHOU ; Yuan ZHOU ; Zheng ZHOU ; Zuhuang ZHOU ; Haiyan ZHU ; Peiyuan ZHU ; Changju ZHU ; Lili ZHU ; Zhengguo WANG ; Jianxin JIANG ; Deqing WANG ; Jiongcai LAN ; Quanli WANG ; Yang YU ; Lianyang ZHANG ; Aiqing WEN
Chinese Journal of Trauma 2024;40(10):865-881
Patients with severe trauma require an extremely timely treatment and transfusion plays an irreplaceable role in the emergency treatment of such patients. An increasing number of evidence-based medicinal evidences and clinical practices suggest that patients with severe traumatic bleeding benefit from early transfusion of low-titer group O whole blood or hemostatic resuscitation with red blood cells, plasma and platelet of a balanced ratio. However, the current domestic mode of blood supply cannot fully meet the requirements of timely and effective blood transfusion for emergency treatment of patients with severe trauma in clinical practice. In order to solve the key problems in blood supply and blood transfusion strategies for emergency treatment of severe trauma, Branch of Clinical Transfusion Medicine of Chinese Medical Association, Group for Trauma Emergency Care and Multiple Injuries of Trauma Branch of Chinese Medical Association, Young Scholar Group of Disaster Medicine Branch of Chinese Medical Association organized domestic experts of blood transfusion medicine and trauma treatment to jointly formulate Chinese expert consensus on blood support mode and blood transfusion strategies for emergency treatment of severe trauma patients ( version 2024). Based on the evidence-based medical evidence and Delphi method of expert consultation and voting, 10 recommendations were put forward from two aspects of blood support mode and transfusion strategies, aiming to provide a reference for transfusion resuscitation in the emergency treatment of severe trauma and further improve the success rate of treatment of patients with severe trauma.
8.A novel O -methyltransferase with substrate promiscuity from Ardisia japonica
Qi LIU ; Rui-qi YAN ; Bing-han XIE ; Song-yang SUI ; Ke-bo XIE ; Jun-gui DAI ; Lin YANG
Acta Pharmaceutica Sinica 2023;58(5):1372-1382
italic>O-methyltransferases (OMTs) are one of the key tailoring enzymes in the biosynthesis of many natural products,
9.Safety and feasibility of 120 min rapid infusion regimen of daratumumab in patients with multiple myeloma.
Tian Hang WANG ; Rui HAO ; Bao Nan XU ; Liang CHANG ; Zhao Bao LIU ; Jia Lin YAO ; Wen WANG ; Wen Jun XIE ; Wen qiang YAN ; Zhi Jian XIAO ; Lu Gui QIU ; Gang AN
Chinese Journal of Hematology 2023;44(8):696-699
10.Scrap management of level Ⅱ biosafety cabinet in some institution
Lin TIAN ; Guan-Jie WANG ; Yan-Jun ZHAO ; Zhong-Xun YI ; Lan-Gui XIE ; Hui-Ying YANG
Chinese Medical Equipment Journal 2023;44(10):91-94
The scrap management of the level Ⅱ biosafety cabinet in some institution from 2019 to 2021 was introduced.The level l[biosafety cabinet was analyzed in terms of the causes for the failures,service length and the correlation between them.Some suggestions were put forward including standardizing the utilization,maintenance and scrap management of the biosafety cabinet.References were provided for ensuring the biosafety and operation of the laboratory.[Chinese Medical Equipment Journal,2023,44(10):91-94]

Result Analysis
Print
Save
E-mail